{"id":"carbenoxolone","rwe":[{"pmid":"41789580","year":"2026","title":"Prenatal lipopolysaccharide exposure programs cardiac fibrosis via dysregulating of connexin 43 in offspring rats.","finding":"","journal":"Molecular medicine reports","studyType":"Clinical Study"},{"pmid":"41775123","year":"2026","title":"Random forest-based QSAR and molecular dynamics insights into steroidal pregnanes as 11β-hydroxysteroid dehydrogenase type 1 modulators for type 2 diabetes.","finding":"","journal":"Computational biology and chemistry","studyType":"Clinical Study"},{"pmid":"41663834","year":"2025","title":"Regulation of the Angiogenic Potential of Endothelial Cells In Vitro under Conditions of Acute Hypoxic Stress: The Role of Homotypic Communication via Gap Junctions.","finding":"","journal":"Bulletin of experimental biology and medicine","studyType":"Clinical Study"},{"pmid":"41645739","year":"2026","title":"Tumor‑associated glucocorticoid inhibition by mifepristone reduces polymorphonuclear myeloid‑derived suppressor cells and promotes antitumor immunity in triple‑negative breast cancer‑bearing mice.","finding":"","journal":"Oncology reports","studyType":"Clinical Study"},{"pmid":"41506545","year":"2026","title":"A comparative in vitro analysis of pannexin1-targeting agents.","finding":"","journal":"Biochemical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"carbenoxolone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Corticosteroid 11-beta-dehydrogenase isozyme 1","category":"target"},{"label":"HSD11B1","category":"gene"},{"label":"A02BX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Peptic ulcer","category":"indication"},{"label":"Ulcer of esophagus","category":"indication"},{"label":"Anti-Ulcer Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"biogastrone","offLabel":[],"synonyms":["carbenoxolone","biogastrone","glycyrrhetinic acid hydrogen succinate","carbenoxolone disodium salt","carbenoxolone disodium","carbenoxolone sodium"],"timeline":[],"brandName":"Biogastrone","ecosystem":[{"indication":"Peptic ulcer","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"dexlansoprazole","slug":"dexlansoprazole","company":"Takeda Pharms Usa"}],"globalPrevalence":64000000},{"indication":"Ulcer of esophagus","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Corticosteroid 11-beta-dehydrogenase isozyme 1","targets":[{"gene":"HSD11B1","source":"DrugCentral","target":"Corticosteroid 11-beta-dehydrogenase isozyme 1","protein":"Corticosteroid 11-beta-dehydrogenase isozyme 1"}],"modality":"Small Molecule","drugClass":"carbenoxolone","explanation":"Think of it like a fire alarm in a building. Cortisol is like a fire that can get out of control and cause damage. Biogastrone is like a fire alarm that sounds when cortisol gets too strong, helping to prevent damage to the stomach and esophagus.","oneSentence":"Biogastrone works by inhibiting the enzyme that converts cortisol into a more potent form, reducing inflammation in the stomach and esophagus.","technicalDetail":"Biogastrone specifically inhibits corticosteroid 11-beta-dehydrogenase isozyme 1, an enzyme that converts cortisol into cortisone, thereby reducing the production of active glucocorticoids and decreasing inflammation in the gastrointestinal tract."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/493","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARBENOXOLONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:10:09.650976","biosimilars":[],"competitors":[{"drugName":"sucralfate","drugSlug":"sucralfate","fdaApproval":"1981-10-30","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bismuth subcitrate","drugSlug":"bismuth-subcitrate","fdaApproval":"2006-09-28","relationship":"same-class"}],"genericName":"carbenoxolone","indications":{"approved":[{"name":"Peptic ulcer","source":"DrugCentral","snomedId":13200003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"Aliment Pharmacol Ther, 2009 (PMID:19220208)"},{"name":"Ulcer of esophagus","source":"DrugCentral","snomedId":30811009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"sucralfate","brandName":"sucralfate","genericName":"sucralfate","approvalYear":"1981","relationship":"same-class"},{"drugId":"bismuth-subcitrate","brandName":"bismuth subcitrate","genericName":"bismuth subcitrate","approvalYear":"2006","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166341","NDDF":"003685","UNII":"MM6384NG73","CHEBI":"CHEBI:31351","INN_ID":"1789","RXNORM":"2017","UMLSCUI":"C0006979","ChEMBL_ID":"CHEMBL499915","KEGG_DRUG":"D01899","DRUGBANK_ID":"DB02329","PDB_CHEM_ID":" CBO","PUBCHEM_CID":"636403","SNOMEDCT_US":"387273006","IUPHAR_LIGAND_ID":"4151","SECONDARY_CAS_RN":"7421-40-1","MESH_DESCRIPTOR_UI":"D002229"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1592,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"A02BX01","allCodes":["A02BX01","A02BX51","A02BX71"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Apr","pmid":"41789580","title":"Prenatal lipopolysaccharide exposure programs cardiac fibrosis via dysregulating of connexin 43 in offspring rats.","journal":"Molecular medicine reports"},{"date":"2026 Feb 25","pmid":"41775123","title":"Random forest-based QSAR and molecular dynamics insights into steroidal pregnanes as 11β-hydroxysteroid dehydrogenase type 1 modulators for type 2 diabetes.","journal":"Computational biology and chemistry"},{"date":"2025 Nov","pmid":"41663834","title":"Regulation of the Angiogenic Potential of Endothelial Cells In Vitro under Conditions of Acute Hypoxic Stress: The Role of Homotypic Communication via Gap Junctions.","journal":"Bulletin of experimental biology and medicine"},{"date":"2026 Apr","pmid":"41645739","title":"Tumor‑associated glucocorticoid inhibition by mifepristone reduces polymorphonuclear myeloid‑derived suppressor cells and promotes antitumor immunity in triple‑negative breast cancer‑bearing mice.","journal":"Oncology reports"},{"date":"2026 Mar","pmid":"41506545","title":"A comparative in vitro analysis of pannexin1-targeting agents.","journal":"Biochemical pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biogastrone, also known as carbenoxolone, is a small molecule drug that targets corticosteroid 11-beta-dehydrogenase isozyme 1. It is used to treat peptic ulcers and ulcers of the esophagus. The commercial status of Biogastrone is unclear, as it is not known whether it is patented or generic, off-patent or not. Key safety considerations are not well-documented. It is not FDA-approved.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}